BioRestorative Therapies
BRTX
14 hedge funds and large institutions have $381K invested in BioRestorative Therapies in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
0.23% more ownership
Funds ownership: 2.94% → 3.17% (+0.23%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
6% less capital invested
Capital invested by funds: $404K → $381K (-$23.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$32.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21K |
| 3 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$17.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.55K |
| 5 |
Morgan Stanley
New York
|
+$4.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$44.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.36K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.96K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$8 |
BRTX Hedge Fund Activity: Q3 2024 in Review
14 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q3 2024, worth a combined $381K — down 5.9% from $404K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BRTX positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $32.9K. The largest seller was UBS Group, cutting an estimated $44.7K.
- 14 institutional investors held BioRestorative Therapies (BRTX) as of Q3 2024, up from 12 in Q2 2024.
- Funds reported $381K of BioRestorative Therapies stock for Q3 2024, down 5.9% quarter-over-quarter.
- 4 funds opened new BioRestorative Therapies positions in Q3 2024 and 1 closed out, a net change of +3 holders.
- The largest BioRestorative Therapies buyer in Q3 2024 was Renaissance Technologies, an estimated $32.9K added.
- The largest BioRestorative Therapies seller in Q3 2024 was UBS Group, an estimated $44.7K sold.
Based on aggregated 13F filings for Q3 2024.